Erratum: A novel epigenetic modulating agent sensitizes pancreatic cells to a chemotherapy agent (PLoS ONE (2018) 13:6 (e0199130) DOI: 10.1371/journal.pone.0199130)

Manjusha Thakar, Yue Hu, Michael Morreale, Lane Lerner, Wan Ying Lin, Rupashree Sen, Yi Cai, Enusha Karunasena, Maya Thakar, Soren Saggi, Harold Keer, Nita Ahuja

Research output: Contribution to journalComment/debatepeer-review

Abstract

There is information missing from the Competing Interests statement. The correct Competing Interests statement is as follows: N.A. was a consultant for Cepheid, and has licensed a bio-marker for early detection of pancreas cancer to Cepheid (PATENT # 10167513). N.A also has grant funding from Astex Pharmaceuticals (GRANT # 120039). N.A. has served as a consultant to Johnson and Johnson, as an advisor to Celgene, and as a member of the Scientific Advisory Council to the No Stomach for Cancer Foundation. H.K. reviewed the manuscript; he is a scientific contributor and Vice President at Astex Inc. This does not alter our adherence to PLOS ONE policies on sharing data and materials.

Original languageEnglish (US)
Article numbere0242974
JournalPloS one
Volume15
Issue number11 November
DOIs
StatePublished - Nov 2020

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)
  • General

Fingerprint Dive into the research topics of 'Erratum: A novel epigenetic modulating agent sensitizes pancreatic cells to a chemotherapy agent (PLoS ONE (2018) 13:6 (e0199130) DOI: 10.1371/journal.pone.0199130)'. Together they form a unique fingerprint.

Cite this